Artiva Biotherapeutics Spotlights RA as Lead NK Cell Program, Eyes H1 Efficacy Data Catalyst at Needham [Yahoo! Finance]
Artiva Biotherapeutics, Inc. (ARTV)
Company Research
Source: Yahoo! Finance
NK cell platform and expects an H1 efficacy data readout in at least 15 RA patients (most with =6 months follow-up) alongside updates on potential pivotal-trial discussions with the FDA. The therapy uses non-genetically modified NK cells plus rituximab to drive deep B-cell depletion and the company is targeting ~50% ACR50 in late-line RA; early autoimmunity data (32 patients) showed no CRS or ICANS and primarily transient cytopenias as the main safety signals. Artiva says one cord unit can yield ~4 trillion NK cells (enough for ~500–1,000 patients) and its 9,000 sq ft facility could treat a similar scale, and the company reported $108 million in cash with runway into Q2 2027 Interested in Artiva Biotherapeutics, Inc.? Here are five stocks we like better. Artiva Biotherapeutics (NASDAQ:ARTV) is prioritizing rheumatoid arthritis (RA) as the lead indication for its non-genetically modified natural killer (NK) cell therapy platform, executives said during a discussion at the Needh
Show less
Read more
Impact Snapshot
Event Time:
ARTV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARTV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARTV alerts
High impacting Artiva Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ARTV
News
- Artiva Biotherapeutics (ARTV) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ARTV&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sMarketBeat
- Artiva Biotherapeutics (ARTV) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ARTV&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from MarketBeat
- Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Artiva Biotherapeutics (ARTV) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ARTV&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sMarketBeat
- Artiva Biotherapeutics (ARTV) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $18.00 price target on the stock.MarketBeat
ARTV
Sec Filings
- 3/10/26 - Form 4
- 3/10/26 - Form S-8
- 3/10/26 - Form 10-K
- ARTV's page on the SEC website